AURKA was regulated by c-Myc which contributes to cancer progression in HCC.[46] Alisertib, an inhibitor of AURKA, could inhibit cell viability and induce apoptosis in HCC cells.[47] Wang et al showed genetic variations of AURKA may be a reliable biomarker for the development of HCC.[48] Our study also indicated that increased expression levels of AURKA were relative to the unfavorable OS and DFS in HCC patients. Here, MYC is linked to cancer.